VANCOUVER, British Columbia, March 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (“Novelion” or the “Company”), today reported preliminary financial results for the fourth quarter and year ended December 31, 2016 and provided an overview of recent business highlights.
“The transformative steps we took in 2016 to realign costs and refocus and intensify our commercial efforts have set us on a strong growth trajectory,” said Mary Szela, Chief Executive Officer of Novelion. “Armed with a portfolio of marketed and innovative development-stage products for rare diseases, and with a pathway to potential new disease indications and commercial markets, we expect to further develop our leadership position in rare metabolic and cardiovascular diseases. In addition to intensifying our commercial efforts around MYALEPT® and JUXTAPID®, both in the U.S. and globally, and continuing our cost reduction efforts, we are exploring new opportunities for metreleptin in a range of low leptin-mediated metabolic rare diseases representing significant unmet medical needs, and we will provide an update on our program prioritization efforts in mid-2017.”
